Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer

Vanderbilt-Ingram Cancer Center10 enrolled

Overview

RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body. PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.

OBJECTIVES: * Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer. OUTLINE: This is a pilot study. Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment. After finishing treatment, patients are followed periodically for up to 10 weeks.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Solid Tumor

Interventions

laboratory biomarker analysisOTHER

laboratory biomarker analysis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of malignancy * Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies) * Normal serum magnesium level Exclusion Criteria: * Glomerular filtration rate ≥ 60 mL/min * No severe underlying renal dysfunction * Normal serum potassium and calcium level * No history of primary or secondary hyperparathyroidism PRIOR CONCURRENT THERAPY: * No prior EGFR pathway inhibitor

Outcomes

Primary Outcomes

Effects of EGFR inhibitors on magnesium homeostasis

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.